Research and Markets: A Fourth Division for Novartis under the Title Vaccines & Diagnostics, Will Be Created After the Acquisition of Chiron Corporation

Business Wire, Sept 1, 2006

DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c41412) has announced the addition of Espicom Business Intelligence's Novartis Prospects to 2010 to their offering.

Novartis was created in 1996 from the merger of the Swiss companies, Ciba and Sandoz. This report provides a full review of the company's activities together with sales forecasts for key products to 2010.

Following the merger of Ciba and Sandoz, the spin-off of the Agribusiness sector and the sale of the remaining activities of the Industry division, Novartis has become a leading company in the life sciences field. Novartis is currently organised into the three divisions of Pharmaceuticals, Consumer Health and Sandoz. A fourth division, Vaccines & Diagnostics, will be created after the acquisition of Chiron Corporation.

Current Growth Drivers

These include: Diovan (valsartan), Glivec/Gleevec (imatinib), Zelmac/Zelnorm (tegaserod), Femara (letrozole) and Zometa (zoledronate).

Key Late-Phase Products Reaching the Market

Lucentis (ranibizumab) is currently filed for age-related macular degeneration.

Two cardiovascular products currently filed have the potential to become mega-blockbusters: Rasilez (aliskiren) for the treatment of hypertension; and Galvus (vildagliptin), indicated for Type II diabetes.

Key Late-Stage Products

Fingolimod is under Phase III development for multiple sclerosis.

Pharmaceutical company intelligence reports provide a full review of the company's activities together with five-year sales forecasts for its key products. The company's financial performance is covered in-depth, from its latest results to a complete analysis of its latest full fiscal year and an outlook for the future. A section on company strategy covers mergers, acquisitions and divestitures, key agreements, products and R&D. An overview of key products and R&D is followed by a comprehensive review of the company's product portfolio and research and development pipeline by therapeutic area. In addition, supplementary appendices provide more in-depth information on financials, agreements and corporate events.

This company report provides Latest Results

A brief review of the latest report results

Executive Summary

At a glance understanding of the major trends and events affecting the company

Financial Analysis (current year)

Detailed P&L and investment review of the latest full year performance

Company Strategy

Where's the company going and how does it plan getting there?

Product/R&D Pipeline

Highly detailed monographs organised by therapeutic category. Also covers R&D strategy/pipeline and provides 5-year sales forecasts to 2010 for major launched products where available

Appendices

5-year financial assessment

Key agreements

Infrastructure

Key pharmaceutical subsidiaries/joint ventures

Product index

The Products Mentioned inside Report:

- Diovan (valsartan)

- Glivec/Gleevec (imatinib)

- Zelmac/Zelnorm (tegaserod)

- Femara (letrozole)

- Zometa (zoledronate)

- Lucentis (ranibizumab)

For more information visit http://www.researchandmarkets.com/reports/c41412